Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation

Journal of Clinical Oncology

Volumn 18, Issue 10, 2000, Pages 2070-2080

  Nieto, Yago ^a   Cagnoni, Pablo J ^a   Nawaz, Samia ^a   Shpall, Elizabeth J ^a   Yerushalmi, Ronit ^a   Cook, Bret ^a   Russell, Peggy ^a   McDermit, Janet ^a   Murphy, James ^a   Bearman, Scott I ^a   Jones, Roy B ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; DISEASE ASSOCIATION; GENE OVEREXPRESSION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; STEM CELL TRANSPLANTATION;

EID: 17144433212     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.10.2070     Document Type: Article

References (56)

1. Reese DM, Slamon DJ: HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells 15:1-8, 1997
2. Mitchell MS, Press MF: The role of immunohistochemistry and fluorescence in situ hybridization for HER-2/neu in assessing the prognosis of breast cancer. Semin Oncol 26:108-116, 1999
3. Paik S, Bryant J, Park C, et al: ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90:1361-1370, 1998
4. Ravdin PM, Green S, Albain KS, et al: Initial report of the SWOG biological correlative study of C-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAFT with tamoxifen (T) alone. Proc Am Soc Clin Oncol 17:97a, 1998 (abstr 374)
5. Muss HB, Thor AD, Berry D, et al: C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994
6. Thor AD, Berry DA, Budman DR, et al: ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90:1346-1360, 1998
7. Seidman AD, Baselga J, Yao T-J, et al: Her-2/neu over-expression and clinical taxane sensitivity: A multivariate analysis in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 15:104a, 1996 (abstr 80)
8. Gianni L, Capri G, Mezzelani A, et al: HER-2/neu (HER2) amplification and response to doxorubicin/paclitaxel (AT) in women with metastatic breast cancer. Proc Am Soc Clin Oncol 16:139a, 1997 (abstr 491)
9. Kirsch DG, Kastan MB: Tumor-suppressor p53: Implications for tumor development and prognosis. J Clin Oncol 16:3158-3168, 1998
10. Elledge RM, Allred DC: Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat 51:79-98, 1998
11. Aas T, Borresen AL, Geisler S, et al: Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2:811-813, 1996
12. Elledge RM, Gray R, Mansour E, et al: Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 87:1254-1256, 1995
13. Berns EMJJ, Klijn JGM, van Putten WLJ, et al: p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer. J Clin Oncol 16:121-127, 1998
14. Elledge RM, Green S, Howes L, et al: bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group study. J Clin Oncol 15:1916-1922, 1997
15. Peters WP, Berry D, Vredenburgh JJ, et al: Five year follow-up of high-dose combination alkylating agents with ABMT as consolidation after standard-dose CAF for primary breast cancer involving ≥ 10 axillary lymph nodes (Duke/CALGB 8782). Proc Am Soc Clin Oncol 14:317a, 1995 (abstr 933)
16. Gianni AM, Siena S, Bregni M, et al: Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary lymph nodes: Five-year results. J Clin Oncol 15:2312-2321, 1997
17. Bearman SI, Overmoyer BA, Bolwell BJ, et al: High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes. Bone Marrow Transplant 20:931-937, 1997
18. Ayash LJ, Elias A, Ibrahim J, et al: High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. J Clin Oncol 16:1000-1007, 1998
19. Cagnoni PJ, Nieto Y, Shpall EJ, et al: High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. J Clin Oncol 16:1661-1668, 1998
20. Peters W, Rosner G, Vredenburgh J, et al: A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): Preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Proc Am Soc Clin Oncol 18:1a, 1999 (abstr 2)
21. b supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy. Proc Am Soc Clin Oncol 18:2a, 1999 (abstr 3)
22. Somlo G, Doroshow JH, Forman SJ, et al: High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: Prognostic indicators of progression-free and overall survival. J Clin Oncol 15:2882-2893, 1997
23. Nieto Y, Cagnoni PJ, Xu X, et al: Predictive model for relapse after high-dose chemotherapy with peripheral blood progenitor cell support for high-risk primary breast cancer. Clin Cancer Res 5:3425-3431, 1999
24. Press MF, Hung G, Godolphin W, et al: Sensitivity of HER-2/ neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54:2771-2777, 1994
25. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
26. Peto R, Peto J: Regression models and life tables. J R Stat Soc A 135:185-188, 1972
27. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
28. Haerslev T, Jacobsen GK: Microwave processing of formalinfixed and paraffin-embedded sections improves the immunoreactivity of c-erhB-2 oncoprotein in breast carcinoma. Appl Immunohistochem 1:223-226, 1993
29. Hsu S-M: Immunohistochemistry, in Meir Wilchek, Edward A. Bayer (eds): Avidin-Biotin Technology: Methods in Enzymology (vol 184). San Diego, CA, Academic Press, 1990, pp 357-363
30. Sjögren S, Inganäs M, Lindgren A, et al: Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 16:462-469, 1998
31. de Cremoux P, Martin EC, Vincent-Salomon A, et al: Quantitative PCR analysis of c-erbB-2 (HEK2/neu) gene amplification and comparison with p185(HER2/neu) protein expression in breast cancer drill biopsies. Int J Cancer 83:157-161, 1999
32. Singleton TP, Niehans GA, Gu F, et al: Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry. Hum Pathol 23:1141-1150, 1992
33. Dykins R, Corbett IP, Henry JA, et al: Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: An immunohistochemical study using monoclonal antibody NCL-CB11. J Pathol 163:105-110, 1991
34. Jacobs TW, Gown AM, Yaziji H, et al: Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 17:1974-1982, 1999
35. Bitran JD, Samuels B, Trujillo Y, et al: Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant therapy. Clin Cancer Res 2:1509-1513, 1996
36. Doroshow JH, Simpson J, Somlo G, et al: Immunohistochemical and histopathologic factors predicting progression-free survival (PFS) and overall survival (OS) following high-dose chemotherapy (HDCT) and stem cell rescue (SCR) for responsive metastatic breast cancer. Proc Am Soc Clin Oncol 15:128a, 1996 (abstr 176)
37. Bezwoda WR: High-dose chemotherapy with haematopoietic rescue in breast cancer. Hematol Cell Ther 41:58-65, 1999
38. Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996
39. Cobleigh M, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999
40. Slamon DL: Alteration of the HER-2/neu gene in human breast cancer: Diagnostic and therapeutic implications. Rosenthal Award Lecture at the 90th Annual Meeting of the American Association for Cancer Research, Philadelphia PA, April 10-14, 1999
41. Slamon D, Leyland-Jones B, Shak S, et al: Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 17:98a, 1998 (abstr 377)
42. Bonsing BA, Corver WE, Gorsira MC, et al: Specificity of seven monoclonal antibodies against p53 evaluated with Western blotting, immunohistochemistry, confocal laser scanning microscopy, and flow cytometry. Cytometry 28:11-24, 1997
43. MacGrogan G, Bonichon F, de Mascarel I, et al: Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases. Breast Cancer Res Treat 36:71-81, 1995
44. Degeorges A, de Roquancourt A, Extra JM, et al: Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer? Breast Cancer Res Treat 47:47-55, 1998
45. Home GM, Anderson JJ, Tiniakos DG, et al: p53 protein as a prognostic indicator in breast carcinoma: A comparison of four antibodies for immunohistochemistry. Br J Cancer 73:29-35, 1996
46. Pratap R, Shousha S: Breast carcinoma in women under the age of 50: Relationship between p53 immunostaining, tumour grade, and axillary lymph node status. Breast Cancer Res Treat 49:35-39, 1998
47. Jacquemier J, Moles JP, Penault-Llorca F, et al: p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: Comparison of staining and PCR-SSCP results. Br J Cancer 69:846-852, 1994
48. Somlo G, Simpson J, Doroshow J, et al: Immunohistochemical (IH) expression of p53, estrogen (ER) and progesterone receptors (PR) and MIB-1 as well as increased mitotic index (MI) are predictors of outcome after high-dose chemotherapy (HDCT) and stem cell rescue (SCR) for high-risk breast cancer (HRBC) patients. Proc Am Soc Clin Oncol 15: 126a, 1996 (abstr 170)
49. Brown JM, Wouters BG: Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 59:1391-1399, 1999
50. Han JW, Dionne CA, Kedersha NL, et al: p53 status affects the rate of the onset but not the overall extent of doxorubicin-induced cell death in rat-1 fibroblasts constitutively expressing c-Myc. Cancer Res 57:176-182, 1997
51. Slichenmeyer WJ, Nelson WG, Slebos RJ, et al: Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res 53:4164-4168, 1993
52. Fan S, Cherney B, Reinhold W, et al: Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment. Clin Cancer Res 4:1047-1054, 1998
53. Fan S, Chang JK, Smith ML, et al: Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene 14:2127-2136, 1997
54. Zamble DB, Jacks T, Lippard SJ: p53-dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells. Proc Natl Acad Sci U S A 95:6163-6168, 1998
55. Bunz F, Hwang PM, Torrance C, et al: Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104:263-239, 1999
56. McGill G, Fisher DE: p53 and cancer therapy: A double-edged sword. J Clin Invest 104:223-225, 1999